GeoVista Co. is a specialized development company for “pet therapeutics” that selects disease targets with high unmet clinical needs and pursues R&D, early clinical entry, and commercialization due to the increase in the number of households owning companion animals (5 million households including pet femmes and pet boomers) and the incidence of chronic and geriatric diseases. In the disease area, we are developing treatments for atopic dermatitis, neutering surgery replacement implants, separation anxiety, and osteoarthritis with high marketability. Currently, three of these pipelines have entered clinical trials, and domestic commercialization and sales are expected in 2026. In addition, we are generating consistent sales by collaborating with global companies on CRO projects necessary for non-clinical research and development targeting pharmaceutical companies and bio ventures, and have a virtuous cycle structure in which generated profits are invested into the development of pet treatments.